Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir

INTRODUCTION: Loss of HBeAg and development of anti-HBe (seroconversion) is seen as a milestone and endpoint in the treatment of HBeAg-positive patients with chronic hepatitis B (CHB). Among patients treated with nucleos (t)ide analogs (NA), recurrent viremia is common after discontinuation of thera...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Dig Dis Sci
Autori principali: Fong, Tse-Ling, Tien, Andy, Jo, Kahee J., Chu, Danny, Cheung, Eddie, Mena, Edward A., Phan, Quang-Quoc, Yu, Andy S., Mohammed, Wafa, Velasco, Andrew, LeDuc, Vinh-Huy, Nguyen, Nickolas, Han, Steven-Bui, Chang, Mimi, Bae, Ho S., Cho, Yong-Won, Tong, Myron J., Cooper, Stewart L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4803449/
https://ncbi.nlm.nih.gov/pubmed/26138653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-015-3775-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi